.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,840,757

« Back to Dashboard
Patent 5,840,757 protects CLINOLIPID 20% and is included in one NDA.

This patent has seventeen patent family members in fourteen countries.

Summary for Patent: 5,840,757

Title: Lipid emulsion intended for parenteral or enteral feeding
Abstract:A lipid emulsion suitable for use as a parenteral or enteral foodstuff, wherein the lipid phase is a mixture of long-chain fatty acids in which 15 to 45% of the total fatty acids are essential fatty acids.
Inventor(s): Dutot; Guy (Noisy le Roi, FR)
Assignee: Clintec Nutrition Company (Deerfield, IL)
Application Number:07/755,610
Patent Claim Types:
see list of patent claims
Compound; Formulation; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Baxter Hlthcare
CLINOLIPID 20%
olive oil; soybean oil
INJECTABLE;INJECTION204508-001Oct 3, 2013RXYes5,840,757► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,840,757

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France87 10407Jul 23, 1987

International Patent Family for Patent: 5,840,757

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria65024► subscribe
Australia1972188► subscribe
Australia609845► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc